Search

Brian Edward Peerce

from Friendswood, TX
Age ~71
Get Report
Also known as:
Brian E Peerce, Brian Dr Peerce
Phone and address:
301 Briarmeadow Ave, Friendswood, TX 77546
(281) 993-9222
Related to:
Desirae M Peerce, 37John Peerce, 36Aryn Williams, 38Brandon Peerce, 39
Connected to:
David W Peercy, 54Emily A Peercy, 40Joan E Peercy, 65Joshua L Peercy, 42Mack H Peercy, 77Rollin E Peercy, 75George Peereboom, 86Frederick C Peerenboom, 90Jeanine D Peerenboom, 44Luke C Peerenboom, 35

Brian Peerce Phones & Addresses

  • 301 Briarmeadow Ave, Friendswood, TX 77546 (281) 993-9222
  • Houston, TX
  • 95 County Road 521, Hanceville, AL 35077
  • Galveston, TX

Work

Company: Duophos Position: Vice president r and d

Industries

Biotechnology

Resumes

Resumes

Brian Peerce Photo 1

Vice President R And D

View page
Location:
Friendswood, TX
Industry:
Biotechnology
Work:
Duophos
Vice President R and D

Business Records

Name / Title
Company / Classification
Phones & Addresses
Brian Peerce
Principal
Duophos
Mfg Biological Products
301 Briarmeadow Ave, Friendswood, TX 77546
Brian Peerce
M
Lsbpgp LLC
301 Briarmeadow Ave, Friendswood, TX 77546

Publications

Us Patents

Inhibitors Of Intestinal Apical Membrane Na/Phosphate Co-Transportation

View page
US Patent:
6787528, Sep 7, 2004
Filed:
Jan 7, 2002
Appl. No.:
10/040708
Inventors:
Brian E. Peerce - Galveston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07F 902
US Classification:
514107, 514576, 558157, 558158, 558160, 558161, 558162, 558163
Abstract:
The compounds of formula (I) are hydrophilic aryl phosphate, thiophosphate, and aminophosphate intestinal apical membrane Na-mediated phosphate co-transportation inhibitors. The compounds can be administered orally, where they act to inhibit Na-dependent phosphate uptake in the intestines, or internally, where they interact with the phosphate control functions of the kidneys and parathyroid. They are therefore useful for inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, and phosphate, and treating renal disease in an animal, including a human.

Napi Type Iib Polypeptides And Methods For Making And Using Same

View page
US Patent:
20030162254, Aug 28, 2003
Filed:
Jan 15, 2003
Appl. No.:
10/345071
Inventors:
Brian Peerce - Friendswood TX, US
International Classification:
C12P021/02
C12N005/06
C07K014/47
C07H021/04
US Classification:
435/069100, 435/320100, 435/325000, 530/350000, 536/023500
Abstract:
Disclosed are isolated NaPiIIb polypeptides. Also disclosed are methods for screening a test compound for its ability to bind to or otherwise affect the function of Na/phosphate cotransporter. The method includes providing an isolated NaPiIIb polypeptide; contacting the isolated NaPiIIb polypeptide with the test compound; and determining whether the test compound binds to or otherwise affects the function of isolated NaPiIIb polypeptide. Antibodies and fragments thereof specific for a isolated NaPiIIb polypeptide are also disclosed.

Inhibition Of Intestinal Apical Membrane Na/Phosphate Co-Transportation In Humans

View page
US Patent:
20030162753, Aug 28, 2003
Filed:
Nov 12, 2002
Appl. No.:
10/292916
Inventors:
Brian Peerce - Friendswood TX, US
International Classification:
A61K031/66
C07F009/02
US Classification:
514/102000, 558/156000, 558/157000
Abstract:
The compounds of formula (I) are hydrophilic aryl phosphate, thiophosphate, and aminophosphate intestinal apical membrane Na-mediated phosphate co-transportation inhibitors. The compounds can be administered orally, where they act to inhibit Na-dependent phosphate uptake in the intestines, or internally, where they interact with the phosphate control functions of the kidneys and parathyroid. They are useful for inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, and phosphate, and treating renal disease in an animal, including a human.

Inhibition Of Intestinal Apical Membrane Na/Phosphate Co-Transportation In Humans

View page
US Patent:
20050187195, Aug 25, 2005
Filed:
Aug 26, 2004
Appl. No.:
10/926841
Inventors:
Brian Peerce - Friendswood TX, US
International Classification:
A61K031/66
US Classification:
514102000, 514120000
Abstract:
The compounds of formula (I) are hydrophilic aryl phosphate, thiophosphate, and aminophosphate intestinal apical membrane Na-mediated phosphate co-transportation inhibitors. The compounds can be administered orally, where they act to inhibit Na-dependent phosphate uptake in the intestines, or internally, where they interact with the phosphate control functions of the kidneys and parathyroid. They are useful for inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, and phosphate, and treating renal disease in an animal, including a human.

Arylfluorophosphate Inhibitors Of Intestinal Apical Membrane Sodium/Phosphate Co-Transport

View page
US Patent:
20130059822, Mar 7, 2013
Filed:
Mar 4, 2011
Appl. No.:
13/582728
Inventors:
Brian Peerce - Friendswood TX, US
Slomowitz Larry - Vancouver, CA
Assignee:
DUOPHOS - Friendswood TX
International Classification:
A61K 31/661
A61P 7/00
A61P 13/12
C07F 9/14
US Classification:
514125, 558195, 558 89
Abstract:
The present invention is directed to fluorophosphates, and pharmaceutical compositions thereof, which are inhibitors of intestinal apical sodium/phosphate co-transport and are useful in the treatment of hyperphosphatemia, in reducing blood phosphate levels, and in treating hypertension.

Inhibitors Of Intestinal Apical Membrane Na/Phoshate Co-Transportation

View page
US Patent:
6355823, Mar 12, 2002
Filed:
Sep 20, 2000
Appl. No.:
09/646654
Inventors:
Brian E. Peerce - Galveston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07F 902
US Classification:
558157, 558158, 558161, 558162, 558163
Abstract:
The compounds of formula (I) are hydrophilic aryl phosphate, thiophosphate, and aminophosphate intestinal apical membrane Na-mediated phosphate co-transportation inhibitors. The compounds can be administered orally, where they act to inhibit Na-dependent phosphate uptake in the intestines, or internally, where they interact with the phosphate control functions of the kidneys and parathyroid. They are therefore useful for inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, and phosphate, and treating renal disease in an animal, including a human.
Control profile
Brian Edward Peerce from Friendswood, TX, age ~71 Get Report